About Tenaya Therapeutics, Inc.
Tenaya Therapeutics was founded with the mission to address chronic heart failure through a multipronged effort focused on the pathologies present in the cardiac muscle. There are no therapies that directly address the core problem of heart failure, the loss of functional cardiac muscle. This major gap in the therapeutic space presents a challenging but significant opportunity for novel regenerative therapies. Our lead research program aims to develop a gene therapy that alters the gene expression of cardiofibroblasts to convert them into cardiomyocytes.
Tenaya is backed by The Column Group with a $50 million Series A investment.